

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT
OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING
THIS POST CARD

Serial No: 08/182,183

Applicants: Lin, et al.

Filed: May 23, 1994 **Examiner:** R. Hayes **Group Art Unit:** 1645

Title: Glial Cell Line-Derived Neurotrophic Factor



6 pgs Amendment After Final Rejection.

S-225E
DRC/khh

Via First Class Mail

July 9, 1999

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

AMGEN

Assistant Commissioner for Patents
Washington, D.C. 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Lin, <i>et al.</i>	Group Art Unit:	1645
Serial No.:	08/182,183	Examiner:	Robert C. Hayes
Filed:	May 23, 1994	Docket No.:	SYNE-225-E (SYNE225/C4-US)
For:	GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR	Date:	July 9, 1999

AMENDMENT AFTER FINAL REJECTION

Box AF
Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

In the Office Action dated June 15, 1999 (Paper No. 44) a shortened statutory period for response was set, ending September 15, 1999. This response is filed within one (1) month of the Office Action.

AMENDMENTS

Applicants respectfully request that the following amendments be entered.

IN THE CLAIMS:

Please cancel claims 91-92 and 136 without prejudice.

89. (Amended) An expression vector for bacterial expression of a glial cell line-derived neurotrophic factor polypeptide comprising a nucleic acid sequence according to Claim 88.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with The United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

July 9, 1999

Date

Signature